The essential role of YAP in ERα36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells

Purpose: Most breast cancers are hormone-receptor-positive, and thus the first-line therapy for them is an anti-estrogen medication such as tamoxifen. If metastasis occurs or resistance to tamoxifen develops, the 5-year survival rates for breast cancer patients significantly decrease. Hence, a better understanding of the molecular mechanisms that contribute to breast cancer aggressiveness is of great importance. ERα36 is an estrogen receptor variant that is known to be upregulated in breast cancer patients receiving tamoxifen treatment or in triple-negative breast cancer cells. However, the specific molecular mechanism underlying ERα36-induced tamoxifen-resistance is not yet fully understood. Methods: ERα36-overexpressing MCF-7 cells were constructed by either plasmid transfection using ERα36 vector or retroviral infection using ERα36-V5-His vector. Target-gene expression was assessed by Western blot analysis and real-time PCR, and YAP activation was evaluated by luciferase assays and immunofluorescence. Cell proliferation and formation of three-dimensional spheroids were evaluated using the IncuCyte S3 Live Cell Analysis System. Results: We found that the expression patterns of Hippo signaling-related genes were significantly changed in ERα36-overexpressing MCF-7 cells compared to MCF-7 cells, which were also similarly observed in tamoxifen-resistant MCF-7 cells. Specifically, the protein expression level and activity of YAP, the core downstream protein of the Hippo pathway, were significantly increased in ERα36-overexpressing MCF-7 cells compared with MCF-7 cells. The aggressive phenotypes acquired by ERα36 overexpression in MCF-7 cells were destroyed by YAP knockout. On this basis, we propose that ERα36 regulates YAP activity by a new mechanism involving Src kinase. Conclusion: Our results suggest that YAP targeting may be a new therapeutic approach to the treatment of advanced breast cancers overexpressing ERα36. Graphical Abstract

[1]  C. Zhang,et al.  YAP inhibits ERα and ER+ breast cancer growth by disrupting a TEAD-ERα signaling axis , 2022, Nature Communications.

[2]  I. Park,et al.  Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells. , 2022, Biochemical and biophysical research communications.

[3]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[4]  J. Lee,et al.  YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant breast cancer and induce transcriptional repression of ERα. , 2021, Journal of cell science.

[5]  K. Kang,et al.  Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance , 2021, Cancer Research.

[6]  F. Ramezani Tehrani,et al.  The role of ERα36 in cell type-specific functions of estrogen and cancer development. , 2020, Pharmacological research.

[7]  E. Ortona,et al.  A Role for Estrogen Receptor alpha36 in Cancer Progression , 2020, Frontiers in Endocrinology.

[8]  Cheng-Ta Yang,et al.  The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC) , 2020, Cancers.

[9]  D. Cheng,et al.  YAP promotes epithelial mesenchymal transition by upregulating Slug expression in human colorectal cancer cells. , 2020, International journal of clinical and experimental pathology.

[10]  D. McCollum,et al.  Control of cellular responses to mechanical cues through YAP/TAZ regulation , 2019, The Journal of Biological Chemistry.

[11]  K. Kang,et al.  Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production , 2019, Scientific Reports.

[12]  K. Kang,et al.  Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. , 2019, Oncology letters.

[13]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[14]  R. Hynes,et al.  SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis , 2018, The Journal of Biological Chemistry.

[15]  S. Milstien,et al.  Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer , 2018, Journal of Lipid Research.

[16]  G. Gores,et al.  YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity , 2018, Molecular Cancer Research.

[17]  E. Song,et al.  Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast cancer by upregulating ALDH1A1 in cancer cells , 2018, Cell Research.

[18]  G. Gores,et al.  Platelet‐derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation , 2018, Journal of cellular biochemistry.

[19]  Kyung Min Kim,et al.  SRC activates TAZ for intestinal tumorigenesis and regeneration. , 2017, Cancer letters.

[20]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[21]  S. Arron,et al.  αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway , 2016, Genes & development.

[22]  Jongshin Kim,et al.  Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation , 2016, The EMBO journal.

[23]  Zhaoyi Wang,et al.  Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer , 2015, Molecular and Cellular Endocrinology.

[24]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[25]  S. Dupont,et al.  The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.

[26]  L. Teng,et al.  ER-α36: a novel biomarker and potential therapeutic target in breast cancer , 2014, OncoTargets and therapy.

[27]  K. Jirström,et al.  Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response , 2014, BMC Cancer.

[28]  Zhongqi Li,et al.  Estrogen receptor‐α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells , 2013, Molecular oncology.

[29]  Zhaoyi Wang,et al.  Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. , 2013, Endocrinology.

[30]  Jill P. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.

[31]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[32]  Zhongqi Li,et al.  Estrogen-independent effects of ER-α36 in ER-negative breast cancer , 2012, Steroids.

[33]  Xintian Zhang,et al.  Estrogen Receptor-Alpha 36 Mediates Mitogenic Antiestrogen Signaling in ER-Negative Breast Cancer Cells , 2012, PloS one.

[34]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[35]  Z. Gatalica,et al.  A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells , 2010, Oncogene.

[36]  Li Li,et al.  The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.

[37]  Liying Yan,et al.  ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways , 2010, PloS one.

[38]  Liying Yan,et al.  A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells , 2009, Reproductive biology and endocrinology : RB&E.

[39]  Yuntao Xie,et al.  Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[41]  Gordon B. Mills,et al.  Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer , 2007 .

[42]  T. Deuel,et al.  A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling , 2006 .

[43]  T. Deuel,et al.  Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66 , 2005 .

[44]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.